Asset Details
Do you wish to reserve the book?
Identification of speckle-type POZ protein somatic mutations in African American prostate cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Identification of speckle-type POZ protein somatic mutations in African American prostate cancer
Do you wish to request the book?
Identification of speckle-type POZ protein somatic mutations in African American prostate cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Identification of speckle-type POZ protein somatic mutations in African American prostate cancer
2014
Overview
The speckle-type POZ protein （SPOP） is a tumor suppressor in prostate cancer （PCa）. SPOP somatic mutations have been reported in up to 15% of PCa of those of European descent. However, the genetic roles of SPOP in African American （AA）-PCa are currently unknown. We sequenced the SPOP gene to identify somatic mutations in 49 AA prostate tumors and identified three missense mutations （p.Y87C, p.F102S, and p.G111E） in five AA prostate tumors （10%） and one synonymous variant （p.11061） in one tumor. Intriguingly, all of mutations and variants clustered in exon six, and all of the mutations altered conserved amino acids. Moreover, two mutations （p.F102S and p.G111E） have only been identified in AA-PCa to date. Quantitative real-time polymerase chain reaction analysis showed a lower level of SPOP expression in tumors carrying SPOP mutations than their matched normal prostate tissues. In addition, SPOP mutations and novel variants were detected in 5 of 27 aggressive PCa and one of 22 less aggressive PCa （P 〈 0.05）. Further studies with increased sample size are needed to validate the clinicopathological significance of these SPOP mutations in AA-PCa.
Publisher
Medknow Publications and Media Pvt. Ltd,Medknow Publications & Media Pvt. Ltd,Medknow Publications & Media Pvt Ltd,Wolters Kluwer Medknow Publications
Subject
African American; mutation analysis; prostate cancer; speckle-type POZ protein
/ Age
/ DNA
/ Humans
/ Male
/ Mutation
/ Original
/ POZ
/ Prostatic Neoplasms - enzymology
/ Prostatic Neoplasms - genetics
/ Proteins
/ Repressor Proteins - genetics
/ Studies
/ Tumors
/ 体细胞突变
/ 前列腺癌
/ 前列腺肿瘤
/ 肿瘤抑制基因
/ 蛋白
/ 鉴别
/ 非洲
